Palo Alto, CA · Founded 2018 · Privately Held (backing)
Developer of artificial intelligence-powered precision therapies designed to address immunology, inflammatory, rare, and oncologic diseases. GEn1E Lifesciences is based in Palo Alto, CA and was founded in 2018. It was valued at $136 million at its early-stage round in Dec 2025, the last priced event on record. It has raised $25.6 million across 2 recorded rounds; the latest was a $5.5 million early-stage round in Oct 2025.
PMV mark · valuation
$135.5M
Oct 2026
Priced at
its early-stage round
Dec 2025
Total raised
$25.6M
Last round
Early Stage VC
Oct 2025
Cap table — not yet on record
GEn1E Lifesciences's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of GEn1E Lifesciences with a free account
·The complete investor list: 38 names
·Watch GEn1E Lifesciences: the Monday email on marks, rounds and moves
Where does GEn1E Lifesciences's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across GEn1E Lifesciences's 2 recorded funding rounds.
